Yousif Capital Management LLC Decreases Holdings in Elevance Health, Inc. $ELV

Yousif Capital Management LLC cut its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,506 shares of the company’s stock after selling 1,925 shares during the quarter. Yousif Capital Management LLC’s holdings in Elevance Health were worth $11,932,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Physician Wealth Advisors Inc. boosted its stake in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the period. Activest Wealth Management lifted its holdings in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the last quarter. Rossby Financial LCC increased its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. Motco increased its stake in shares of Elevance Health by 334.8% during the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares during the period. Finally, True Wealth Design LLC increased its stake in shares of Elevance Health by 431.8% during the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after buying an additional 95 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 2.1%

Shares of NYSE:ELV opened at $318.39 on Thursday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $444.37. The business’s fifty day simple moving average is $312.51 and its 200-day simple moving average is $332.18. The company has a market capitalization of $69.94 billion, a PE ratio of 12.67, a P/E/G ratio of 1.65 and a beta of 0.49. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period last year, the business posted $3.84 EPS. The business’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were issued a $1.72 dividend. The ex-dividend date was Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.2%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is 27.39%.

Wall Street Analyst Weigh In

ELV has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Guggenheim cut their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Sanford C. Bernstein cut their price target on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Robert W. Baird raised their price target on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Finally, Wells Fargo & Company lowered their price objective on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Twelve equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $385.38.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.